ΨΥΧΟΛΟΓΙΑ - Έρευνα και Εφαρμογές ΤΕΥΧΟΣ 4ο | Page 65

ΙSSN: 2623- 3673
Φεβρουάριος, 2019
Ψυχολογία :έρευνα & εφαρμογές
ΒΙΒΛΙΟΓΡΑΦΙΑ
1. Igwe S, Brigo F. Clin Psychopharmacol Neurosci. 2018 Aug 31; 16(3):235-
245. Does Melatonin and Melatonin Agonists Improve the Metabolic Side
Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of
Randomized Controlled Trials.
2. Tréhout M, Dollfus S. Encephale. 2018 Jul 5. Physical activity in patients
with schizophrenia: From neurobiology to clinical benefits.
3. Stoner S. Ment Health Clin. 2018 Mar 23; 7(6):246-254. Management of
serious cardiac adverse effects of antipsychotic medications.
4. Eich P, Nick B.Ther Umsch. 2018 Jun; 75(1):9-17. Pharmacotherapy of
schizophrenia spectrum disorders: State of the Art.
5. Manolis T, Manolis A, Manolis A. Angiology. 2018 Jan. Cardiovascular
Safety of Psychiatric Agents: A Cautionary Tale.
6. Correll C, Rubio J, Kane J. World Psychiatry. 2018 Jun; 17(2):149-160. What
is the risk-benefit ratio of long-term antipsychotic treatment in people with
schizophrenia?
7. Chacko E, Boyd S, Murphy R. Int Psychogeriatr. 2018 May 25:1-10.
Metabolic side effects of atypical antipsychotics in older adults.
8. Li R, Ou J, Li L, Yang Y, Zhao J, Wu R. Front Pharmacol. 2018 Apr 16;
9:379.
The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced
Weight Gain and Insulin Resistance.
9. Kamath A, Rather Z A.Biomed Res Int. 2018 Feb 21.Melatonin for Atypical
Antipsychotic-Induced Metabolic Adverse Effects: A Meta-Analysis of
Randomized Controlled Trials.
10. Bruno A, Pandolfo G, Crucitti M, Troili G, Spina E, Zoccali R, Muscatello
M. Complement Ther Med. 2018 Apr; 37: 167-171. Red Yeast Rice (RYR)
supplementation in patients treated with second-generation antipsychotics.
11. Whicher C, Price H, Holt R. Eur J Endocrinol. 2018 Jun; 1 78(6)
Mechanisms in endocrinology: Antipsychotic medication and type 2 diabetes and
impaired glucose regulation.
12. Siskind D, Friend N, Russell A, McGrath J, Lim C, Patterson S, Flaws D,
Stedman T, Moudgil V, Sardinha S, Suetani S, Kisely S, Winckel K, Baker A
BMJ Open. 2018 Mar 2; 8(3) CoMET: a protocol for a randomised controlled
trial of co-commencement of METformin as an adjunctive treatment to attenuate
weight gain and metabolic syndrome in patients with schizophrenia newly
commenced on clozapine.
13. Krivoy A, Onn R, Vilner Y, Hochman E, Weizman S, Paz A, Hess S, Sagy
R, Kimhi-Nesher S, Kalter E, Friedman T, Friedman Z, Bormant G, Trommer S,
Valevski A, Weizman A. EBioMedicine. 2017 Dec; 26: 138-145. Vitamin D
Supplementation in Chronic Schizophrenia Patients Treated with Clozapine: A
Randomized, Double-Blind, Placebo-controlled Clinical Trial.